JCAD

Across TCGA pan-cancer cohorts, JCAD RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated JCAD data layer compared with 8 for mutation status and 6 for mass-spec protein.

The strongest signal is observed in uveal melanoma (UVM), where higher JCAD RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated JCAD expression acts as an unfavorable survival marker, although some lineages such as KIRC and THCA show a favorable association.

UVM, KIRP, and STAD are the cancer types where JCAD RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UVM	DFS	Median	All	0.416	0.734	<.001	125	view →
KIRP	DFS	Quartile	II,III,IV	0.161	0.703	<.001	93	view →
STAD	OS	Quartile	All	0.218	0.590	<.001	69	view →
KIRC	OS	Median	All	0.853	0.758	<.001	63	view →
THCA	DFS	Median	All	0.947	0.674	<.001	42	view →
HNSC	DFS	Tertile	IV	0.761	0.563	.005	34	view →
LGG	DFS	Tertile	All	0.880	0.767	<.001	31	view →
MESO	OS	Median	All	0.427	0.669	.001	29	view →
LUAD	OS	Tertile	II,III,IV	0.695	0.343	.004	23	view →
ACC	OS	Quartile	IV	1.000	0.282	.004	21	view →
BLCA	DFS	Quartile	All	0.225	0.520	.004	19	view →
COAD	DFS	Median	All	0.380	0.592	.008	17	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

JCAD–UVM (DFS)

Open the UVM breakdown →